SWX:NWRNPharmaceuticals
Did Launching the ENIGMA-TRS 2 Phase III Trial Just Shift Newron Pharmaceuticals' (SWX:NWRN) Investment Narrative?
Newron Pharmaceuticals has initiated its ENIGMA-TRS 2 global Phase III trial of evenamide as an add-on therapy for treatment-resistant schizophrenia, following US FDA and IRB approvals, with the first site at UCLA’s Semel Translational Research Center for Neuropsychiatry.
The study’s focus on rigorously defined treatment-resistant patients and evenamide’s targeted sodium-channel mechanism highlights its potential differentiation from existing antipsychotic options.
Next, we’ll explore how...